Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
letter
. 1981 Sep;12(3):429–431. doi: 10.1111/j.1365-2125.1981.tb01240.x

Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility.

C S Deacon, M S Lennard, N D Bax, H F Woods, G T Tucker
PMCID: PMC1401820  PMID: 6117306

Full text

PDF
429

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bax N. D., Tucker G. T., Woods H. F. Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol. 1980 Oct;10(4):353–361. doi: 10.1111/j.1365-2125.1980.tb01771.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Conrad K. A., Nyman D. W. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980 Oct;28(4):463–467. doi: 10.1038/clpt.1980.189. [DOI] [PubMed] [Google Scholar]
  3. Facino R. M., Lanzani R. Interaction of a series of beta-adrenergic blocking drugs with rat hepatic microsomal monooxygenase. Pharmacol Res Commun. 1979 May;11(5):433–445. doi: 10.1016/s0031-6989(79)80007-7. [DOI] [PubMed] [Google Scholar]
  4. Greenblatt D. J., Franke K., Huffman D. H. Impairment of antipyrine clearance in humans by propranolol. Circulation. 1978 Jun;57(6):1161–1164. doi: 10.1161/01.cir.57.6.1161. [DOI] [PubMed] [Google Scholar]
  5. Jack D. B. Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists? Br J Clin Pharmacol. 1981 Apr;11(4):402–406. doi: 10.1111/j.1365-2125.1981.tb01145.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Johnsson G., Regårdh C. G., Sölvell L. Lack of biological interaction of alprenolol and salicylate in man. Eur J Clin Pharmacol. 1973 Jun;6(1):9–14. doi: 10.1007/BF00561794. [DOI] [PubMed] [Google Scholar]
  7. Keenaghan J. B., Boyes R. N. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther. 1972 Feb;180(2):454–463. [PubMed] [Google Scholar]
  8. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  9. Neil-Dwyer G., Bartlett J., McAinsh J., Cruickshank J. M. Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol. 1981 Jun;11(6):549–553. doi: 10.1111/j.1365-2125.1981.tb01169.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Peet M., Middlemiss D. N., Yates R. A. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet. 1980 Nov 1;2(8201):978–978. doi: 10.1016/s0140-6736(80)92135-2. [DOI] [PubMed] [Google Scholar]
  11. Topham J. C. Relationship between difference spectra and metabolism. Barbiturates, drug interaction and species difference. Biochem Pharmacol. 1970 May;19(5):1695–1701. doi: 10.1016/0006-2952(70)90160-7. [DOI] [PubMed] [Google Scholar]
  12. Woods P. B., Robinson M. L. An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents. J Pharm Pharmacol. 1981 Mar;33(3):172–173. doi: 10.1111/j.2042-7158.1981.tb13743.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES